Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Morphine
Actimorph
Routinely available
Local application
07/02/2024
Indication
Severe pain which can be managed adequately only by opioids. Restriction: Used as an alternative for patients unable to swallow morphine sulphate ‘Sevredol’ tablets, or where a lower dose is required and unable to measure morphine sulphate oral solution due to dexterity issues or visual impairment.
Therapeutic Area
Central nervous system
Status Description
Routinely available in line with local or regional guidance
Formulation
Immediate release orodispersible tablet